An update on ocular effects of anti-diabetic medications.

IF 5.1 2区医学 Q1 OPHTHALMOLOGY

Survey of ophthalmology Pub Date : 2025-01-22 DOI:10.1016/j.survophthal.2025.01.010

Elham Sadeghi, Elham Rahmanipour, Nicola Valsecchi, Saloni Kapoor, Maria Vittoria Cicinelli, Jay Chhablani

{"title":"An update on ocular effects of anti-diabetic medications.","authors":"Elham Sadeghi, Elham Rahmanipour, Nicola Valsecchi, Saloni Kapoor, Maria Vittoria Cicinelli, Jay Chhablani","doi":"10.1016/j.survophthal.2025.01.010","DOIUrl":null,"url":null,"abstract":"<p><p>The global increase in the prevalence of type 2 diabetes has led to the development and implementation of new classes of anti-diabetic medications, introducing advanced therapeutic options for the management of the disease. These new medications, though primarily designed to regulate blood glucose levels, also have applications in weight management, potentially transforming the current approaches to diabetes treatment. Newer medications, however, have ophthalmic side effects with controversies in trials and real-life data. We conducted a comprehensive assessment of the ocular benefits and adverse effects of both traditional and newer-generation anti-diabetic drugs. Our primary focus is on how these newer medications affect the stage of diabetic retinopathy. Additionally, we explore the associations between these medications and other ocular conditions, including age-related macular degeneration, glaucoma, orbital conditions, and diseases impacting the ocular surface. Furthermore, we provide contextual background by discussing the ocular effects of traditional anti-diabetic drugs.</p>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Survey of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.survophthal.2025.01.010","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The global increase in the prevalence of type 2 diabetes has led to the development and implementation of new classes of anti-diabetic medications, introducing advanced therapeutic options for the management of the disease. These new medications, though primarily designed to regulate blood glucose levels, also have applications in weight management, potentially transforming the current approaches to diabetes treatment. Newer medications, however, have ophthalmic side effects with controversies in trials and real-life data. We conducted a comprehensive assessment of the ocular benefits and adverse effects of both traditional and newer-generation anti-diabetic drugs. Our primary focus is on how these newer medications affect the stage of diabetic retinopathy. Additionally, we explore the associations between these medications and other ocular conditions, including age-related macular degeneration, glaucoma, orbital conditions, and diseases impacting the ocular surface. Furthermore, we provide contextual background by discussing the ocular effects of traditional anti-diabetic drugs.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Survey of ophthalmology 医学-眼科学

CiteScore

10.30

自引率

2.00%

发文量

138

审稿时长

14.8 weeks

期刊介绍： Survey of Ophthalmology is a clinically oriented review journal designed to keep ophthalmologists up to date. Comprehensive major review articles, written by experts and stringently refereed, integrate the literature on subjects selected for their clinical importance. Survey also includes feature articles, section reviews, book reviews, and abstracts.